A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.
about
Brief History and Characterization of Enhanced Respiratory Syncytial Virus DiseaseInduction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine designMucosal vaccines against respiratory syncytial virusIntranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics.Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice.Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of AgeCharacterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSVBacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applicationsStructural and biochemical insights into the V/I505T mutation found in the EIAV gp45 vaccine strain.Repurposing staples for viruses: applying peptide design to RSV prophylaxis.Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine DesignUnmet needs in respiratory diseases : "You can't know where you are going until you know where you have been"--Anonymous.The common cold: potential for future prevention or cure.Exploiting the peptidoglycan-binding motif, LysM, for medical and industrial applicationsRecent advances in the development of subunit-based RSV vaccines.Surface display on lactic acid bacteria without genetic modification: strategies and applications.Biophysical characterization of the type III secretion tip proteins and the tip proteins attached to bacterium-like particles.Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development.Immunosilencing a highly immunogenic protein trimerization domain.Lactococcus lactis As a Versatile Vehicle for Tolerogenic Immunotherapy.Microbiota Composition and the Integration of Exogenous and Endogenous Signals in Reactive Nasal Inflammation.Kinetic analysis of the influenza A virus HA/NA balance reveals contribution of NA to virus-receptor binding and NA-dependent rolling on receptor-containing surfacesRotavirus VP6 protein mucosally delivered by cell wall-derived particles from Lactococcus lactis induces protection against infection in a murine model
P2860
Q26775152-2DC3A1DE-63DB-4AB1-AFE4-312C9AA42B2DQ27021304-144702A5-5A48-4FC3-9897-090015A7BD44Q33837530-FA9E6453-994C-47EA-824B-A70C1D04C941Q34309830-7D158056-EAD3-4E31-B44B-50F7F66AD2D9Q35672965-C7976B43-2FCF-43E7-8D03-EBA8E82B7EB8Q35946462-954834AB-90C1-4C23-8762-7931BA26AB5EQ36263882-6B78AD4E-6178-4BD1-A4EB-97090ABBDE2CQ37002523-EE3A6CA6-7177-4F53-8508-1440EB67F105Q37177598-1F41B01C-5372-4B4C-92D1-E93D329D2B11Q37720380-C8BE02D8-15A2-4DBE-8C4F-5A5E3D18AC04Q37726694-F87DEEC6-BB68-40AE-8498-64AE38EEE160Q37729137-CD315BBC-8662-4AEB-AFDD-5D24AF690612Q38167718-863E0CA1-B79B-44C7-97A7-8648E6C3E2EEQ38177756-02470CDD-87C8-46CA-BCBD-F52B54BD7E61Q38197928-32CF19E0-30BB-497D-ABC8-9ADF951D23D4Q38617302-1DFA2B9B-D4A1-410A-8182-39CC087A312AQ38959870-CC4978BE-D18F-4070-BE9B-DEB8237AD7C1Q39177635-14545E92-FD22-4522-B812-B42611317710Q40812866-F8C3CCAC-21BB-4A82-B9A6-C0A8E9545CA6Q41506957-72AF2023-B9C4-42F0-A460-15A6E64E194CQ49444745-D746C087-B0C5-4081-BB5D-F6B84B38AAFDQ55424073-2E853D4A-AED6-4332-882F-148D486B80E4Q56965280-F7CECA82-17A3-4296-9466-107BCD1E6F88Q58759991-167CA352-BD53-486E-9D80-A2F4BE451D40
P2860
A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A protective and safe intranas ...... d to bacterium-like particles.
@ast
A protective and safe intranas ...... d to bacterium-like particles.
@en
A protective and safe intranas ...... d to bacterium-like particles.
@nl
type
label
A protective and safe intranas ...... d to bacterium-like particles.
@ast
A protective and safe intranas ...... d to bacterium-like particles.
@en
A protective and safe intranas ...... d to bacterium-like particles.
@nl
prefLabel
A protective and safe intranas ...... d to bacterium-like particles.
@ast
A protective and safe intranas ...... d to bacterium-like particles.
@en
A protective and safe intranas ...... d to bacterium-like particles.
@nl
P2093
P2860
P1433
P1476
A protective and safe intranas ...... d to bacterium-like particles.
@en
P2093
Alan Rigter
Bert Jan Haijema
Cornelis A M de Haan
Frank E J Coenjaerts
Hanneke Versantvoort
Ivy Widjaja
Kees Leenhouts
Maarten van Roosmalen
P2860
P304
P356
10.1371/JOURNAL.PONE.0071072
P407
P577
2013-08-12T00:00:00Z